Medicinal Cannabis Access in Western Australia

Who actually controls medicinal cannabis access in Western Australia, Canberra or Perth? The honest answer is both, at different points in the process, and that overlap is where most of the confusion starts. This article sets out how the two layers fit together, in general terms, for education only.

Medicinal cannabis access in WA: the two frameworks to understand first

Western Australia sits inside Australia's federal scheduling architecture, which means the TGA's Poisons Standard sets the baseline. State law then layers on top. Understanding which body controls what is the thing most people get wrong, and honestly, I get why. The division of responsibility isn't obvious from a standing start. If you want the wider picture of how that split works across the country, our piece on state versus federal drug regulation in Australia covers it.

At the federal level, medicinal cannabis products containing tetrahydrocannabinol (THC) are scheduled as Schedule 8 (Controlled Drug) under the Poisons Standard. Cannabidiol (CBD) products meeting specific low-dose criteria were down-scheduled to Schedule 4 (Prescription Only) in 2021, though the S4 CBD pathway carries strict concentration limits that most clinical products sit above. So the practical reality is: the vast majority of medicinal cannabis products that reach patients in WA are controlled drugs requiring Schedule 8 prescriptions.

A schedule is simply a classification that decides how tightly a substance is controlled: who may supply it, whether a prescription is needed, and how it must be stored and recorded. Schedule 4 medicines need a prescription. Schedule 8 medicines need a prescription plus additional record-keeping and authorisation requirements, which is why the schedule a product falls into shapes everything downstream. For more on the CBD side of this, see our explainer on CBD and down-scheduling in Australia.

The TGA manages two federal access pathways, the Special Access Scheme (SAS, specifically Category B for unapproved products) and the Authorised Prescriber scheme. Products listed on the ARTG can be prescribed without SAS approval, but there are currently very few registered medicinal cannabis products on the ARTG compared with the volume of SAS-B approvals being granted nationally. If the register itself is unfamiliar, the ARTG and the difference between registered and unregistered medicines is a useful companion read.

Where Western Australian state law fits in

WA's relevant state instrument is the Medicines and Poisons Act 2014 (WA) and its associated regulations. Under this Act, Schedule 8 substances require a Schedule 8 prescription, and prescribing S8 medicines in WA generally requires the prescriber to hold an S8 prescriber approval issued by the WA Department of Health's Medicines and Poisons Regulation branch, unless a specific exemption applies.

This is where WA diverges slightly from some other states. In New South Wales, for instance, the equivalent approval process has historically been managed differently, and our New South Wales regulatory overview shows how. WA's S8 prescriber approval requirement means that a GP wanting to prescribe a THC-containing product to a patient must first obtain that state-level approval. That's a separate step from the TGA's SAS-B or Authorised Prescriber process; both are required.

A common mistake is to treat a TGA approval as the finish line. It isn't. The federal decision answers the question of whether an unapproved product can be supplied to a patient. The state decision answers whether this particular prescriber is permitted to write the Schedule 8 prescription in the first place. Two different regulators, two different questions.

There is an exemption pathway for specialist medical practitioners prescribing in the course of specialist practice, but the details here matter and change. Prescribers and patients should always check the current position directly with the WA Department of Health's Medicines and Poisons Regulation branch, because this is exactly the kind of detail that shifts with regulatory updates and I'd rather point you to the source than give you a number that's already out of date.

The federal access routes in practice

SAS Category B is the workhorse. Under this pathway, a registered medical practitioner applies to the TGA for approval to prescribe an unapproved medicinal cannabis product for a specific patient. The TGA assesses the application, turnaround times have improved substantially since the early days, and if approved, the product can be dispensed through a pharmacy with the appropriate Schedule 8 authorisations in place. Our Special Access Scheme Category B page goes through the mechanics, and the broader guide to the Special Access Scheme places Category B alongside the other categories.

The Authorised Prescriber scheme works differently. A medical practitioner applies to the TGA (with endorsement from a Human Research Ethics Committee or a specialist college, in most cases) to be authorised to prescribe a specific unapproved medicinal cannabis product across a class of patients, without needing individual SAS approvals for each patient. The scheme suits higher-volume prescribers once established, but the initial approval process is more involved.

It's easy to assume Authorised Prescribers would dominate, since one approval covers many patients. The data suggests SAS-B has remained the dominant mechanism numerically, partly because the entry bar is lower for occasional prescribers. A practitioner who sees only a handful of relevant patients has little reason to go through the heavier up-front process. For national figures on how the pathways are used, see patient access data in Australia.

What products are available and how they're classified

Products reaching WA patients through lawful pathways must comply with TGA Good Manufacturing Practice (GMP) requirements, either Australian GMP or an equivalent recognised overseas standard. This matters for product quality assurance and distinguishes these products from unregulated material. In plain terms, GMP is a quality system covering how a medicine is made, tested and documented, so that one batch matches the next.

The pharmacological profile of a product depends heavily on its cannabinoid composition. Most approved products contain some combination of CBD and THC, though some are CBD-dominant or THC-dominant. The broader class of cannabinoids found in cannabis, including cannabigerol (CBG), is increasingly represented in research literature, though most approved products remain focused on the primary cannabinoids. Full-spectrum and broad-spectrum extracts are available through various approved products, as are isolate-based formulations. Roughly speaking, full-spectrum extracts retain a wider range of plant compounds, broad-spectrum extracts retain some of them, and isolates contain a single purified compound. The labels are descriptive terms, not regulatory categories, so it pays to read what a product's documentation actually states.

How a product is formulated also affects its bioavailability. Oil-based oral preparations undergo significant first-pass metabolism, which influences the effective dose reaching systemic circulation. These are pharmacological realities that sit in the prescriber's domain, not the patient's, but they're worth understanding in the broader regulatory picture. Australia also groups products into numbered categories, which our page on medicinal cannabis product categories explains.

Driving, employment, and legal possession limits in WA

This section gets asked about a lot, and rightly so. WA's Road Traffic (Administration) Act 2008 provides for roadside drug testing that detects THC presence, not impairment, in oral fluid. A lawful medicinal cannabis prescription does not exempt a patient from a positive roadside test under WA law. The WA Police Force conducts these tests, and a positive result can lead to infringement or charge regardless of the prescription status of the substance.

This is, in my view, a genuine policy tension that hasn't been fully resolved in any Australian jurisdiction. The science of how long THC remains detectable in oral fluid relative to actual impairment is an active research area, and the current WA framework is blunt by design. Patients prescribed THC-containing products should be acutely aware of this before making decisions about driving; that guidance comes directly from the WA Department of Health's own public materials. We cover the topic in more depth in driving laws and prescribed cannabis in Western Australia.

The same logic tends to apply at work. Workplace policies are set by employers and by safety obligations in particular industries, and a prescription does not automatically override them. Anyone in a safety-sensitive role should raise it with their prescriber and their employer rather than assume.

On possession: a patient with a valid Schedule 8 prescription, dispensed through an authorised WA pharmacy, is in lawful possession of the quantity dispensed. Possessing or using cannabis outside those parameters remains a criminal matter under WA's Misuse of Drugs Act 1981.

The pharmacy dispensing chain

Not all WA pharmacies stock or dispense Schedule 8 medicinal cannabis products. Pharmacies require their own Schedule 8 permits under WA law to dispense these medicines, and the supply chain from importer or manufacturer to dispensing pharmacy involves several regulated steps. Patients and prescribers working through dispensing logistics often find this the most practically frustrating part of the access system, particularly in regional WA, where the distance between a patient in, say, the Pilbara and an appropriately authorised compounding or dispensing pharmacy can be substantial.

Each step in that chain has its own paperwork: the importer or manufacturer, any wholesaler involved, and the pharmacy that finally supplies the patient. A delay at any link can hold up the whole process, which is one reason timing a prescription renewal is a practical matter and not only an administrative one.

The dispensing logistics that look manageable on paper in Perth look very different when you map them against the actual geography of a state this large. That gap between regulatory design and on-ground reality is worth naming plainly.

Keeping up with changes

The medicinal cannabis regulatory landscape in Australia has moved quickly since 2016, and WA-specific requirements have evolved alongside federal reforms. For the background, see Australia's 2016 medicinal cannabis legalisation. The TGA's regulatory guidance documents are updated periodically; the WA Department of Health publishes current S8 prescriber requirements on its Medicines and Poisons Regulation pages. Both sources should be treated as primary, not summaries of them, including this one.

For anyone wanting to understand the pharmacological side of what these products contain and how cannabinoids interact with the endocannabinoid system, our glossary has entries across the major cannabinoids and receptors worth working through separately. Common questions are also gathered in our medicinal cannabis access FAQ.

The regulatory framework described here reflects publicly available information as at mid-2024. Laws change. Always verify current requirements with the TGA and the WA Department of Health directly before relying on any summary for clinical or compliance purposes.

Sources

• Accessing medicinal cannabis products in Australia; TGA (Therapeutic Goods Administration)
• Medicinal cannabis, WA Department of Health
• Guidance on the use of the Poisons Standard, TGA (Therapeutic Goods Administration)
• Cannabis; Alcohol and Drug Foundation (ADF)

Marcus Hale, Regulatory researcher, TGA & access law